p53 gene mutation with or without allelic loss has been considered to be the commonest alteration found in sporadic non-familial cancer (Vogelstein, 1990) . This alteration occurs in a wide variety of tumour types, including solid and haematopoietic tumours (Hollstein et al, 1991) . Furthermore, humans who inherit germline p53 mutations are prone to the development of cancer (Marklin et al, 1990; Srivastava et al, 1990) .
The wild-type p53 appears to function as a cell-growth suppressor and may play an important role in genomic stability and DNA repair (Zambetti et al, 1993) . Wild-type p53 transactivates the WAFI/p21 gene (El-Deiry et al, 1993; Harper et al, 1993) , whose protein product prevents exit from the G,-phase by inhibiting cyclin/Cdk complexes and, in parallel, blocks replicative DNA synthesis by binding to proliferating cell nuclear antigen (PCNA) (Dulic et al, 1994; Waga et al, 1994) . When DNA is altered, the cell cycle is blocked in G,-phase, allowing time for repair (Kastan et al, 1991 (Kastan et al, , 1992 . If the DNA damage is too great, the cell is engaged in the apoptosis pathway and is subsequently deleted from the tissue (Clarke et al, 1993; Lowe et al, 1993) . p53, therefore, acts as 'the guardian of the genome . However, the molecular mechanism of wild-type p53 action is not fully understood. The p53 protein has been shown to activate several genes by interacting with specific DNA sequences, such as the promoter of muscle specific creatine kinase (Weintraub et al, 1991) and the third intron of the GADD-45 gene, which is induced after gamma irradiation (Papathanasiou et al, 1991) . A consensus p53 DNA-binding site has been derived from these studies (Kern et al, 1991; El-Deiry et al, 1992; Funke et al, 1992) . Wild-type p53 has also been implicated in the transcriptional inhibition of several genes involved in cell growth: c-myc (Moberg et al, 1992) , retinoblastoma susceptibility gene (Shiio et al, 1992) , multidrug resistance gene-I (Chin et al, 1992) , proliferating cell nuclear antigen (Subler et al, 1992) , c-fos, interleukin 6, c-jun and hsc70, a member of the heat shock family (Ginsberg et al, 1991; Santhanam et al, 1991; Agoff et al, 1993) . This inhibitory effect might be caused by a direct action on the TATA box machinery (Liu et al, 1993; Thut et al, 1995) . p53 was also found to be able to stimulate its own transcription, but was unable to bind directly the specific sequences, which have been identified in the p53 promoter (Deffie et al, 1993) .
In colorectal cancer, p53 mutations and allelic losses on 17p are genomic alterations that occur as late events in tumour progression (Baker et al, 1990; Fearon et al, 1990) . p53 gene mutations have been associated with poor prognosis in human breast carcinomas (Thorlacius et al, 1993) and in non-small-cell lung cancer (Horio et al, 1993) . In colorectal cancer, a strong correlation has been observed between the presence of a mutation and short survival (Hamelin et al, 1994) . In contrast to previous findings (Kern et al, 1989) , when tumours were classified according to their histological stage, a multivariate Cox model analysis showed that p53 mutation, rather than 17p allelic losses, was the only independent prognostic factor (Hamelin et al, 1994) . Immunohistochemistry (IHC) studies have indicated that mutated p53 is overexpressed in premalignant head and neck lesions (Shin et al, 1994) , oesophageal squamous cell carcinomas (Wagata et al, 1993) , ovarian cancer (Kupryjanczyk et al, 1993) , breast cancer (Faille et al, 1994) and hepatocellular carcinoma (Wolkmann et al, 1994) . In colorectal cancer, overexpression of p53 protein has been correlated with poor short-term prognosis (Yamaguchi et al, 1992;  p53 mRNA overexpression in colorectal cancer 529 1 00C 1OC 10 100'
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Most authors attributed p53 protein overexpression to an increase in its half-life owing to the conformational changes induced by mutations (Zambetti et al, 1993) , but this mechanism is not relevant in the case of wild-type overexpression. In order to define more clearly p53 gene expression, we analysed in this study p53 mRNA expression in 109 colorectal carcinomas by the use of a semi-quantitative reverse transcription -polymerase chain reaction (RT-PCR) technique and examined its relationship to p53 mutation.
MATERIALS AND METHODS Materials
This study was performed on a series of 109 specimens obtained from patients undergoing resection of colorectal adenocarcinoma between January 1992 and November 1994. Auvinen et al, 1994) . However, the literature concerning the prognostic value ofp53 immunoreactivity is controversial, as the results of IHC assays cannot be accepted as evidence of p53 gene mutation (Battifora et al, 1994) . In addition, there is no clear picture concerning the significance of wild-type overexpression observed in several studies on colorectal adenomas (Pignatelli et al, 1992; Pignatelli et al, 1992; Tominaga et al, 1993) and demonstrated in anaplastic astrocytomas (Lang et al, 1994) , breast cancer (Moll et al, 1992) , melanomas (Castresana et al, 1993) , testis cancer (Peng et al, 1993) and hepatic tumours of childhood (Kennedy et al, 1994 Primer 11 Sense Intron 6 5'-GTC TCC CCA AGG CGC ACT GG-3' Primer 12
Antisense Intron 7 5'-GAT GTG ATG AGA GGT GGA T-3' Set 7
Primer 13 
PCR amplification
All primers and probes, used to optimize RT-PCR procedures, were synthesized using a 391 DNA synthesizer (Applied Biosystem, Foster City, CA, USA), followed by high-performance liquid chromatography. The fluorescent-labelled primers, used to measure mRNA levels and to sequence the PCR products, were purchased from Genset Corporation (France). 
Quantitation of PCR products
The optimal number of cycles of amplification to allow quantitation of p53 and 3-actin gene PCR products was determined using primers 5 and 6 for p53 and 15 and 16 for P-actin, the primers 5 and 15 being coupled to a fluorophore. The PCR products for each cycle were subjected to 6% polyacrylamide gel electrophoresis (PAGE). The size of the PCR products, as well as the intensity of the fluorescence, were automatically measured and integrated using the genescan software (version 1.2) in an ABI model 373 (Applied Biosystem). We obtained a linear increase in the signal between 22 and 26 cycles for p53 and f-actin in tumour and adjacent normal mucosa samples. To test the reproducibility and linearity of the data, eight different samples (tumour and their adjacent normal mucosa samples) were chosen randomly ( Figure  1 ). The appropriate number of PCR cycles for detection and quantification of p53 and ,B-actin DNA fragments lay between 20 and 26 cycles and first-strand cDNA was therefore used directly for 26 cycles of PCR amplification. So, the amount of p53 mRNA was expressed in arbitrary units (AU), which represented the value of the ratio between the fluorescent signal of p53 cDNA and P-actin cDNA after 26 cycles.
p53 cDNA sequencing All samples showing a high p53 mRNA level were tested to determine the entire coding sequence of the p53 cDNA. After an additional reverse transcription, four different PCRs (100 g1 of reaction mixture) with each set of primers 1 to 4 (Table 1) were performed in order to amplify overlapping fragments of the total cDNA. After 35 cycles of PCR, the primers and oligonucleotides were recovered from the reaction mixture using a centricon 100 microconcentrator (Amicon, Beverly, MA, USA). Specific p53 amplification products were identified by electrophoresis on 2% agarose gels. The PCR products (100 ng) were subjected to sequencing reactions using the Prism reaction dideoxyterminator kit according to the protocol supplied by the manufacturer (Applied BioSystem). Taq sequencing reactions were carried out in a Perkin-Elmer thermocycler 9600 as follows: 30 s at 96°C, 15 s at 50°C and 4 min at 60°C for 25 cycles. Extended fragments were purified from nonincorporated nucleotides and primers through quick TM spin columns (Boehringer). The reaction mixtures were then dried, resuspended in 4 gl of dionized formamide: 50 mM EDTA, pH 8.0, heated for 2 min at 90°C, transferred on ice and loaded immediately onto a 6% denaturating polyacrylamide gel. Gels were run for 12 h at 30 W constant power on an ABI model 373 A automated DNA sequencer.
p53 genomic DNA sequencing Samples without p53 mRNA overexpression were sequenced after amplification of genomic DNA. In these cases, the primers used for DNA amplification are summarized in was observed, we also demonstrated coexpression of the wild-type allele. This is visible on the sequence spectrum by the presence of two bases at the same position (data not shown). However, it is impossible to sequence p53 cDNA from normal tissue by RT-PCR. The level of p53 mRNA was significantly higher in tumours expressing the mutated-type allele alone (0.86 ± 0.47 AU) than in tumours also expressing the wild-type allele (0.56 ± 0.31 AU) or in tumours with non-mutated p53 (0.56 ± 0.32 AU) ( Table 2 ). In four of the 40 tumours without mRNA overexpression, we found p53 gene mutation associated with wild-type allele expression.
Relationship between p53 gene alterations and clinicopathological features
The frequency of mutation was not statistically different according to the Dukes' stage (P=0.40) or the location (P=0.5) ( Table 3 ). The (1997) 75(4), [528] [529] [530] [531] [532] [533] [534] [535] [536] dinucleotides), while eight of them (22.2%) were transversions. Three point mutations created a stop at codons 148, 186 and 193, while 33 out of 44 (75%) missense mutations were detected: 21 were found at codons 175, 245, 248, 273 and 272 located in major mutational 'hotspots', frequently affected in colorectal cancer (Greenblatt et al, 1994) . Nine of these mutations concerned codon number 273 (six CGT -> TGT, R -4 C and three CGT -> CAT, R -> H); in these tumours, the p53 mRNA level was either 0.46 + 0.22 AU when the wild-type allele was expressed or 0.87 ± 35 AU when not expressed. These results are identical to those obtained with respect to all mutated tumours expressing the wild-type allele (or not) ( Table 2 ). Six of the missense mutations affected codon number 248 (four CGG --CAG, R -e Q and two CGG -> TGG, R -e W), two of the missense mutations affected codon number 175 (CGC -X CAC, R -4 H and CGC -o GGC, R -e G) and the codon number 245 (GGC -* GGA, G -* D and GGC -* TGC, G -e C). We also found two mutations at codon number 272 (GTG -> ATG, V --M and GTG -> TTG, V -4 L).
Eight mutations created major rearrangements of the mRNA reading frame (Table 4) , four of them were insertions or deletions of one basepair. Deletions of cytosine 983 at codon 257 (tumour 147), adenine 1052 at codon 280 (tumour 164) and cytosine 1115 at codon 301 (tumour 9) gave three putative p53 proteins composed of 343 amino acids differing in their C-terminus. Insertion of a thymine after the guanine 989 at codon 259 (tumour 199) gave a putative shorter polypeptide composed of 262 amino acids. In four cases, more marked rearrang'ements were observed: a large rearrangement (tumour 121) in the N-terminus (from nucleotide 1 to 129), a non-homologous recombination of 43 basepairs after nucleotide 97 (tumour 44), a deletion of nine bases (amino acids 177 to 179, PHH) (tumour 194) and an insertion of five bases after nucleotide 1002 at codon 263 (tumour 155) giving a p53 protein composed of 343 amino acids. These eight rearrangements all concerned advanced Dukes' stage (seven were Dukes' stage C and one was Dukes' stage D).
DISCUSSION
In this series of 109 primary colorectal carcinomas, we observed pS3 mRNA overexpression in 63% of the cases. This overexpression occurred without any correlation with the stage or site of the disease. The mean level ofp53 mRNA expression is five-to sixfold higher in these tumours than in adjacent normal mucosa. Some tumours showed high p53 mRNA levels, while others showed a slight increase. In the latter case, p53 mRNA may either be weakly expressed in all tumour cells or highly expressed in a few tumour cells owing to tumour heterogeneity. Indeed, it has been described that the tumour cell staining varied in extent and intensity when p53 protein is detected by IHC (Zeng et al, 1994) . Our results clearly demonstrate that p53 regulation may occur at a pretranslational step, involving either an increase in p53 gene expression and/or stabilization of its mRNA. Our findings confirm earlier reports, which showed an elevated level ofp53 transcripts in 28 (Gope et al, 1991) and 25 (Lothe et al, 1992) cases, 70% and 66% of tested tumours overexpressed p53 respectively. In these studies, p53 mRNA quantification was performed by Northern blot analysis.
When DNA sequencing was performed, 44 tumours (40%) exhibited p53 mutation. Our data on the prevalence and spectra of p53 mutations in colorectal cancer agree with those obtained from 960 cases compiled by Greenblatt et al (1994) . However, the most striking difference between the two studies concerns the number of non-missense type mutations, which accounted for 18% of mutations in our study vs 8% in Greenblatt's study. Among the 36 substitutions of a single basepair, 28 of them occurred at CpG dinucleotides; the p53 coding region contains 39 CpG dinucleotides, which are potential sites for the methylation of cytosine. Recently, Tornaletti et al (1995) found that the p53 sequences along exons 5-8 were completely methylated at every CpG site, whatever the tissue. Methylation of CpG dinucleotides is thought to be the cause of the genetic changes occurring through spontaneous deamination of 5-methylcytosine (Rideout et al, 1990) and accounted for the majority of endogenous mutations in vertebrates (Sved et al, 1990) . In our study, mutated and wild-type alleles were expressed simultaneously in 25 tumours, and the loss of wild-type allele expression was rarely observed in the proximal colon (25%) vs 50% and 43% in the distal colon and the rectum respectively. The rectum is a site in which a high incidence of 17p allelic loss has been observed. These differences were not statistically significant, and the hypothesis that genetic mechanisms leading to cancer differ in the proximal and distal colon needs to be verified (Delattre et al, 1989) .
In 40 of the 44 mutated tumours, p53 mRNA levels were significantly higher in tumours expressing the mutated allele alone than in tumours expressing both wild-and mutated-type alleles. It has been described that p53 stimulates its own transcription (Deffie et al, 1993) , and that some p53 mutant forms presented wild-type transactivation activity (Levine et al, 1991) . In addition, p53 can induce transcription from an internal promoter located within the mdm2 gene (Juven et al, 1993) , whose product, MDM2 oncoprotein, has been identified as a negative regulator of the p53 gene. Further, MDM2, by binding to p53, inhibits its ability to activate transcription and may, therefore, be part of a negative feedback loop serving to terminate signals involving the transient activation of wild-type p53 (Oliner et al, 1992; . So, when a p53 gene mutation occurs, the absence of a negative feedback might be responsible for p53 mRNA overexpression. The suppressor function of wild-type p53 may also be compromised in cells containing a mutant allele of p53, since the formation of wild-type -mutant p53 inactive complexes occurs (Milner et al, 1991) . Thus, mutant forms abrogate the ability of wild-type p53 to transactivate appropiate target genes in vitro and in vivo (Farmer et al, 1992; Kern et al, 1992) , and the relative quantity of mutated to wild-type p53 mRNA could determine the transformed phenotype, and the result could be partial or complete loss of wild-type function. p53 mRNA overexpression can account for an elevated content of p53 protein in the absence of p53 gene mutation. An increase in wildtype p53 has been observed in colorectal adenomas and has been suggested to constitute an early event in the process of adenoma formation and carcinogenesis (Tominaga et al, 1993; Boccuzzi, 1995) ; our present data showing no correlation between p53 mRNA and tumour stage agree with these results. Other results suggest that, in colorectal cancer, IHC detection of p53 protein does not always indicate the existence of an underlying p53 gene mutation (Dix et al, 1994) . This abnormal expression of wild-type p53 protein was also found in normal cells of a patient from a family with a history of cancer (Barnes et al, 1992) and, more recently, a new case of Li-Fraumeni was reported in which no mutation in the coding sequence of the p53 gene was detected (Birch et al, 1994) . In all cases, stabilization of the p53 protein depends on factors other than p53 gene mutation, such as (1) binding to other molecules of cellular (mdm2 gene product) or viral origin blocking p53 in an inactive conformation; and/or (2) (Lang et al, 1994) , melanomas (Castresana et al, 1993) and testis cancer (Peng et al, 1993) , and that nuclear exclusion of p53 might also be one way of inactivating p53 in breast cancer (Moll et al, 1992) . Nuclear exclusion of wild-type p53 is suggested in a study showing its cytoplasmic accumulation in colorectal cancers (Bosari et al, 1995) with a higher prevalence in advanced tumours (Sun et al, 1992) . Another study has shown an increase in p53 protein according to the stage of carcinomas from the rectum (Starzynska et al, 1992) . In our study, the level of p53 mRNA did not correlate with either the Dukes' stage or the tumour site, in accordance with previous data showing no correlation in colorectal cancers between p53 overexpression detected by IHC and clinicopathological data (Yamaguchi et al, 1992, ; Bosari et al, 1994) . This lack of correlation between p53 overexpression (either mRNA or protein) and tumour stage suggests that it is an early event in these tumours, perhaps beginning with adenoma formation (Tominaga et al, 1993) . p53 mRNA overexpression with or without p53 mutation suggests two distinct mechanisms of inactivation leading to the development of cancer, and that the p53 status might have important implications for cancer therapy. The tumour-suppressing function of p53 preserves genome integrity and the p53 protein is required for apoptosis in response to radiation-induced DNA damage, a mechanism serving to eliminate potentially oncogenic cells (Lee et al, 1993) . The relation between p53 mutations and the therapeutic response has been verified in vivo in athymic nude mice injected with embryonic transformed fibroblasts differing in their p53 status. Tumours expressing the wild-type p53 gene contained a high proportion of apoptotic cells and typically regressed after gamma radiation or doxorubicin treatment. In contrast, wild-type p53-deficient tumours continued to grow and contained few apoptotic cells (Lowe et al, 1994) . These data show that much benefit could be gained from identifying cancers without p53 mutations, which are likely to respond more favourably to drug therapy than those with mutated p53. Conversely, patients whose tumours harbour p53 mutations might be spared from the toxicity associated with chemotherapy agents and would be good candidates for novel therapeutic approaches. Recently, Fujiwara et al (1994) (Kinzler et al, 1994) . Analysis of the level of p53 mRNA in colorectal cancer by quantitative RT-PCR provides a rapid and sensitive method for discriminating between tumours overexpressing p53 mRNA with or without p53 gene mutation. This should be useful for future anti-tumour research and for the design of therapeutic agents specific to the inactivation process. The observation period in our study was too short to clarify the relationship between p53 mRNA overexpression and clinical prognosis of patients with a colorectal carcinoma; we are following these patients.
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